Novo Nordisk’s GLP-1 drug Semaglutide, sold under brand names Ozempic and Wegovy, has been hailed as a miracle drug for ...

Shares of Hims & Hers (HIMS) are down $3.47, or 8%, to $37.50 in pre-market trading after a court denied a motion for a preliminary ...

Novo Nordisk is introducing a direct-to-patient delivery option for its flagship weight loss drug Wegovy (semaglutide), ...

Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of ...

Why Warren Buffett was selling stocks, Marvell’s outlook fails to wow Wall Street, and more news to start your day.

The FDA recently announced that Novo Nordisk’s semaglutide GLP-1 medication (Ozempic and Wegovy) is no longer in short supply ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

It’s designed to prevent decay by strengthening enamel. But it isn’t always covered by insurance, especially for adults.

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients without insurance.

The Consumer Financial Protection Bureau is dropping its lawsuit against the company that runs the Zelle payment platform and three U.S. banks as federal agencies continue to pull back on ...

BofA analyst Allen Lutz reiterated an Underperform rating and $21 price target on Hims & Hers (HIMS) after Novo Nordisk (NVO) announced ...